- Report of Foreign Issuer (6-K)
2009年9月29日 - 6:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of September 2009
Commission File Number: 0-29350
VASOGEN INC.
(Translation of registrant’s name into English)
4
ROBERT SPECK PARKWAY, 15TH FLOOR
MISSISSAUGA, ONTARIO L4Z 1S1
(Address of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1).
o
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of
a Form 6-K if submitted solely to provide an attached annual report to
security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
o
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of
a Form 6-K if submitted to furnish a report or other document that the
registrant foreign private issuer must furnish and make public under the laws
of the jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrant’s “home country”), or under the rules of
the home country exchange on which the registrant’s securities are traded, as
long as the report or other document is not a press release, is not required to
be and has not been distributed to the registrant’s security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether the registrant by
furnishing the information contained in this Form is also thereby
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
Yes
o
No
x
If “Yes” is marked,
indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82- .
|
Exhibit
|
|
Title
|
|
|
|
|
|
99.1
|
|
Notice
of Special Meetings and Joint Management Information Circular with respect to
the proposed arrangement involving Vasogen Inc., 7231971 Canada Inc., 7232004
Canada Inc., Cervus LP and Cervus GP Ltd. and the proposed arrangement and
merger of Vasogen Inc., 7231971 Canada Inc. and 7232004 Canada Inc. and
IntelliPharmaCeutics Ltd., IntelliPharmaCeutics Corp., 7237081 Canada Inc.
and 20090831 Delaware Inc. to form IntelliPharmaCeutics International Inc.,
dated September 16, 2009, as filed with CSA on September 28, 2009
|
|
|
|
|
|
99.2
|
|
Notice
of Special Meeting to shareholders of Vasogen Inc., dated September 16,
2009, as filed with CSA on September 28, 2009
|
|
|
|
|
|
99.3
|
|
Form of
Letter of Transmittal with respect to Common Shares of Vasogen Inc., as filed
with CSA on September 28, 2009
|
|
|
|
|
|
99.4
|
|
Form of
Vasogen Inc Proxy, as filed with CSA on September 28, 2009
|
|
|
|
|
|
99.5
|
|
Voting Agreement,
dated August 14, 2009 and related amendment, between Patrick Yat,
IntelliPharmaCeutics Ltd. and Vasogen Inc.,
as filed with CSA on
September 28, 2009
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
(Registrant)
VASOGEN INC
.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Graham Neil
|
|
|
|
Name:
|
Graham
Neil
|
|
Date:
September 28, 2009
|
|
Title:
|
Vice
President, Finance and
Chief Financial Officer
|
2
EXHIBIT INDEX
|
Exhibit
|
|
Title
|
|
|
|
|
|
99.1
|
|
Notice
of Special Meetings and Joint Management Information Circular with respect to
the proposed arrangement involving Vasogen Inc., 7231971 Canada Inc., 7232004
Canada Inc., Cervus LP and Cervus GP Ltd. and the proposed arrangement and
merger of Vasogen Inc., 7231971 Canada Inc. and 7232004 Canada Inc. and
IntelliPharmaCeutics Ltd., IntelliPharmaCeutics Corp., 7237081 Canada Inc.
and 20090831 Delaware Inc. to form IntelliPharmaCeutics International Inc.,
dated September 16, 2009, as filed with CSA on September 28, 2009
|
|
|
|
|
|
99.2
|
|
Notice
of Special Meeting to shareholders of Vasogen Inc., dated September 16,
2009, as filed with CSA on September 28, 2009
|
|
|
|
|
|
99.3
|
|
Form of
Letter of Transmittal with respect to Common Shares of Vasogen Inc., as filed
with CSA on September 28, 2009
|
|
|
|
|
|
99.4
|
|
Form of
Vasogen Inc Proxy, as filed with CSA on September 28, 2009
|
|
|
|
|
|
99.5
|
|
Voting Agreement,
dated August 14, 2009 and related amendment, between Patrick Yat,
IntelliPharmaCeutics Ltd. and Vasogen Inc.,
as filed with CSA on
September 28, 2009
|
3
Vasogen (NASDAQ:VSGN)
過去 株価チャート
から 5 2024 まで 6 2024
Vasogen (NASDAQ:VSGN)
過去 株価チャート
から 6 2023 まで 6 2024
